Clinical Trial Update: Itacitinib + Everolimus in Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updating the combination of Itacitinib and Everolimus for Classical Hodgkin lymphoma with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Everolimus (everolimus)
• Itacitinib (itacitinib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Classical Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-30